ISDA

Deposition Date 2016-06-15

Release Date 2016-09-21

Last Version Date 2023-09-27

Entry Detail

PDB ID:

5KHM

Keywords:

Transcription Factor

Title:

The first BET bromodomain of BRD4 bound to compound 13 in a bivalent manner

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.48 Å

R-Value Free:

0.21

R-Value Work:

0.17

R-Value Observed:

0.18

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Bromodomain-containing protein 4
Gene (Uniprot):BRD4
Chain IDs:A, B
Chain Length:127
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:O60885 Pfam ID:PF00439

Ligand Molecules

GOL

XNH

Primary Citation

Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).

Bradbury, R.H, Callis, R, Carr, G.R, Chen, H, Clark, E, Feron, L, Glossop, S, Graham, M.A, Hattersley, M, Jones, C, Lamont, S.G, Ouvry, G, Patel, A, Patel, J, Rabow, A.A, Roberts, C.A, Stokes, S, Stratton, N, Walker, G.E, Ward, L, Whalley, D, Whittaker, D, Wrigley, G, Waring, M.J.Show

J.Med.Chem. 59 7801 7817 (2016)

PMID: 27528113 DOI: 10.1021/acs.jmedchem.6b00070

Abstact

Here we report the discovery and optimization of a series of bivalent bromodomain and extraterminal inhibitors. Starting with the observation of BRD4 activity of compounds from a previous program, the compounds were optimized for BRD4 potency and physical properties. The optimized compound from this campaign exhibited excellent pharmacokinetic profile and exhibited high potency in vitro and in vivo effecting c-Myc downregulation and tumor growth inhibition in xenograft studies. This compound was selected as the development candidate, AZD5153. The series showed enhanced potency as a result of bivalent binding and a clear correlation between BRD4 activity and cellular potency.

Legend

Protein

Chemical

Disease

Primary Citation of related structures